Meticulous Research Releases New Report - Molecular Diagnostics Market Expected to Hit $46.69 Billion by 2030

Meticulous Research Releases New Report: Molecular Diagnostics Market Expected to Hit $46.69 Billion by 2030 Meticulous Research , a renowned leader in providing comprehensive market research solutions, has unveiled its newest report titled "Molecular Diagnostics Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab) - Global Forecast to 2030." This groundbreaking report forecasts the molecular diagnostics market to reach an estimated value of $46.69 billion by 2030, showcasing a notable CAGR of 5.6% from 2023 to 2030. Driving Forces Behind Market Expansion The report attributes the robust growth of the molecular diagnostics market to several pivotal factors. These include the escalating global geriatric population, the surge in both communicable and non-communicable diseases, continuous technological advancements in molecular diagnostics, and the escalating healthcare expenditures worldwide. Additionally, burgeoning opportunities in emerging economies, a growing emphasis on companion diagnostics, and the increasing popularity of direct-to-consumer (DTC) genetic testing are anticipated to further fuel significant market expansion. Download Free Sample Report: https://www.meticulousresearch.com/download- sample-report/cp_id=5375 Molecular Diagnostics Advancements Amidst the COVID-19 Pandemic During the unprecedented COVID-19 pandemic, manufacturers intensified efforts to develop diverse diagnostic kits and assays for early disease detection, expected to propel market growth in the coming years. Notable developments during this period include: In May 2022, Cepheid (a subsidiary of Danaher) (U.S.) obtained CE Mark for Xpert Xpress CoV-2 plus, a test for qualitative detection of COVID-19. In May 2021, F. Hoffmann-La Roche Ltd (Switzerland) received Emergency Use Authorization (EUA) from the U.S. FDA for cobas SARS-CoV-2 test, designed for individuals without COVID-19 symptoms or suspicions. In November 2020, BioM rieux S.A. (France) secured CE mark for the SARS-CoV-2 R-GENE test, a part of the ARGENE range for SARS-CoV-2 detection. In September 2020, Hologic, Inc. (U.S.) received Emergency Use Authorization (EUA) from the U.S. FDA for asymptomatic COVID-19 testing with Panther Fusion SARS-CoV-2 Assay. Browse in depth @ https://www.meticulousresearch.com/product/molecular- diagnostics-market-5375 Furthermore, companies operating in the diagnostics market conducted web meetings and webinars during this period to engage with customers and stakeholders, providing detailed product descriptions and customer demonstrations, thereby enhancing end-user awareness.

Market Segmentation and Growth Trends The molecular diagnostics market is segmented based on Product & Service, Test Type, Technology, Application, End User, and Geography. Key insights include: Product & Service: The kits & reagents segment is anticipated to hold the largest market share in 2023, driven by the frequent utilization of diagnostic kits, an extensive portfolio of disease- specific kits, and technological advancements. Test Type: Laboratory tests are expected to dominate the market in 2023, preferred by hospitals, laboratories, and academic & research institutes. Technology: PCR is projected to lead the market in 2023, owing to its sensitivity, rapid amplification capabilities, and cost-effectiveness compared to other technologies. Application: Infectious diseases are forecasted to account for the largest market share in 2023, fueled by rising incidence rates and government initiatives promoting early diagnosis. End User: Hospitals & clinics are expected to hold the largest market share in 2023, attributed to their extensive range of diagnostic tests and patient volume. Geographic Analysis North America is anticipated to command the largest market share in 2023, followed by Europe and Asia-Pacific, driven by advanced infrastructure, favorable reimbursement policies, increased healthcare accessibility, and a high volume of laboratory tests. Quick Buy @ https://www.meticulousresearch.com/Checkout/18320359 Key Players Leading players in the molecular diagnostics market include F. Hoffmann-La Roche Ltd, Hologic, Inc., QIAGEN N.V., Danaher Corporation, bioM rieux S.A., and Becton, Dickinson and Company (BD), among others. Contact: Mr.Khushal Bombe Meticulous Market Research Inc. 1267WillisSt,Ste200 Redding, California,96001, U.S. USA: +1-646-781-8004 Europe : +44-203-868-8738 APAC: +91 744-7780008 Email-sales@meticulousresearch.com Visit Our Website:https://www.meticulousresearch.com/ Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research